Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

497 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy.
Pfob A, Sidey-Gibbons C, Lee HB, Tasoulis MK, Koelbel V, Golatta M, Rauch GM, Smith BD, Valero V, Han W, MacNeill F, Weber WP, Rauch G, Kuerer HM, Heil J. Pfob A, et al. Among authors: valero v. Eur J Cancer. 2021 Jan;143:134-146. doi: 10.1016/j.ejca.2020.11.006. Epub 2020 Dec 8. Eur J Cancer. 2021. PMID: 33307491
Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy.
Buchholz TA, Katz A, Strom EA, McNeese MD, Perkins GH, Hortobagyi GN, Thames HD, Kuerer HM, Singletary SE, Sahin AA, Hunt KK, Buzdar AU, Valero V, Sneige N, Tucker SL. Buchholz TA, et al. Among authors: valero v. Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):880-8. doi: 10.1016/s0360-3016(02)02850-x. Int J Radiat Oncol Biol Phys. 2002. PMID: 12095553
Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer.
Huang E, McNeese MD, Strom EA, Perkins GH, Katz A, Hortobagyi GN, Valero V, Kuerer HM, Singletary SE, Hunt KK, Buzdar AU, Buchholz TA. Huang E, et al. Among authors: valero v. Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1225-33. doi: 10.1016/s0360-3016(02)02878-x. Int J Radiat Oncol Biol Phys. 2002. PMID: 12128124
T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy.
Garg AK, Strom EA, McNeese MD, Buzdar AU, Hortobagyi GN, Kuerer HM, Perkins GH, Singletary SE, Hunt KK, Sahin A, Schechter N, Valero V, Tucker SL, Buchholz TA. Garg AK, et al. Among authors: valero v. Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):138-45. doi: 10.1016/j.ijrobp.2003.10.037. Int J Radiat Oncol Biol Phys. 2004. PMID: 15093909
Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy.
Buchholz TA, Huang EH, Berry D, Pusztai L, Strom EA, McNeese MD, Perkins GH, Schechter NR, Kuerer HM, Buzdar AU, Valero V, Hunt KK, Hortobagyi GN, Sahin AA. Buchholz TA, et al. Among authors: valero v. Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1337-42. doi: 10.1016/j.ijrobp.2004.02.018. Int J Radiat Oncol Biol Phys. 2004. PMID: 15275718
497 results